Actively Recruiting
Evaluating Mepolizumab and In-Office Nasal Polypectomy for Chronic Rhinosinusitis with Nasal Polyps A Three-Group Randomized Study
Led by Instituto de Investigación Marqués de Valdecilla · Updated on 2026-09-11
75
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial studies adults aged 18 to 70 years with chronic rhinosinusitis with nasal polyps who require surgery and meet criteria for biologic treatment based on the EPOS 2020 guideline. It evaluates the effects of combining in-office nasal polypectomy with mepolizumab treatment compared to either treatment alone, aiming to identify the most effective approach for managing this condition. Participants are assigned to one of three groups one group undergoes nasal polypectomy without mepolizumab, another receives mepolizumab alone 100 mg subcutaneously every 4 weeks for 12 doses alongside daily topical corticosteroid use, and the third group undergoes polypectomy followed by mepolizumab treatment started during or within 48 hours after surgery. The trial includes five study visits with clinical assessments including questionnaires and nasal endoscopy. During the study, participants will be evaluated through clinical questionnaires, nasal endoscopy, and monitoring of adverse effects. The primary outcome is change in sinonasal outcome test SNOT-22 score at 52 weeks. Secondary outcomes include nasal polyp severity, symptom improvements, need for rescue corticosteroids, and treatment-related adverse events over 12 months. Participants are followed regularly throughout the year-long study to assess these outcomes and monitor safety.
CONDITIONS
Brief Title
Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here